What period do Curatis Holding AG’s reported financial results cover?

The reported financial results cover the year ended 31 December 2025. Curatis noted that Curatis AG was consolidated for eight months in 2024, compared with 12 months in 2025.

How much revenue did Curatis Holding AG report for 2025?

Curatis Holding AG reported business revenues of CHF 10.8m for 2025, representing growth of 57%. Product sales amounted to CHF 10.3m and service revenue amounted to CHF 0.5m.

Why did Curatis Holding AG’s distribution revenue increase in 2025?

Curatis Holding AG said revenues in its distribution business increased organically by 13%, from CHF 9.5m in 2024 to CHF 10.8m in 2025. The company attributed the increase mainly to products from new contracts.

Did Curatis Holding AG remain loss-making in 2025?

Yes, Curatis Holding AG reported a net loss of CHF 1.4m for 2025, although this was lower than the loss of CHF 4.3m reported for the previous year.

How much cash did Curatis Holding AG have at the end of 2025?

Curatis Holding AG reported a cash position of CHF 1.9m as of 31 December 2025. The company also said it raised CHF 1.2m in November 2025 to progress corticorelin.

What milestone did Curatis Holding AG achieve with the FDA for corticorelin?

Curatis Holding AG said its development plan for corticorelin was validated at a meeting with the FDA in September 2025. This enabled the company to proceed towards a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema, or PTBE.

What is the planned design of Curatis Holding AG’s Phase 3 corticorelin trial?

Curatis Holding AG said the planned Phase 3 trial will use an adaptive design consisting of a dose-optimisation lead-in and a confirmatory segment. The trial is intended to support approvals in the US and Europe.

What are the terms of Curatis Holding AG’s corticorelin licensing agreement in Japan?

Curatis Holding AG said Neupharma Co., Ltd., Tokyo, will initially develop corticorelin in Japan for children and adolescents, and will finance and conduct a pivotal clinical trial to support a filing for approval in Japan. Curatis will receive upfront and milestone payments for regulatory and commercial targets totalling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%.

What does Curatis Holding AG expect for revenue and profitability in 2026?

Curatis Holding AG expects revenue growth of over 25% in 2026 compared with 2025 and said its objective remains to achieve a break-even result in 2026. These are forward-looking statements based on the company’s current expectations, assumptions, estimates and projections, and Curatis cautioned that actual results may differ materially.

What are the next planned steps for Curatis Holding AG’s corticorelin programme?

Curatis Holding AG said its partner Neupharma plans to meet Japan’s regulatory authority, PMDA, to discuss the registration-enabling study in summer 2026, with the clinical study expected to start in 2027. Curatis also said it is advancing preparatory work for the pivotal Phase 3 study supporting potential approvals in the US and Europe, alongside global partnering activities.

What is Curatis Holding AG developing corticorelin to treat?

Curatis Holding AG is developing its lead product candidate, C-PTBE-01, also called corticorelin, to treat peritumoral brain edema associated with primary and metastatic brain tumours. Curatis said corticorelin is an investigational drug and is not approved for therapeutic use in the United States or outside the United States.

Where do Curatis Holding AG’s shares trade and what is the ticker symbol?

Curatis Holding AG is identified in the announcement as listed on SIX under the ticker symbol SIX:CURN.

When will Curatis Holding AG hold its next Annual General Meeting?

Curatis Holding AG said its Annual General Meeting will take place on 22 May 2026 at 14:30 in Pratteln. The company also said there will be no presentation on the annual figures, but it will be available to answer questions.

Home
News Intelligence
Curatis Holding AG
Curatis reports 2025 revenue growth as corticorelin programme advances

Back to all Curatis Holding AG press releases

Curatis Holding AG

SIX:CURN

Curatis reports 2025 revenue growth as corticorelin programme advances

Published Tuesday, 24 March 2026, 06:00 AM

Get alerts

Plain English summaries when Curatis Holding AG announces news.

At a glance

Company: Curatis Holding AG
Listings: SIX:CURN
Announcement type: Financial results
Published: Tuesday, 24 March 2026, 06:00 AM
Reporting period: 2025
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period	Compared with
Business revenues	CHF 10.8m	2025	Not stated
Net result	a loss of CHF 1.4m	2025	a loss of CHF 4.3m in 2024
Product sales	CHF 10.3m	2025	Not stated
Cash position	CHF 1.9m	as of 31 December 2025	Not stated
Upfront and milestone payments	up to CHF 83.5 million	Not stated	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Curatis Holding AG (SIX:CURN, “Curatis”) reported 2025 financial results and updates on corticorelin development and a Japan licensing agreement.

Business revenues were CHF 10.8m (+57%) for 2025.
Curatis AG reported distribution revenue of CHF 10.8m (CHF 9.5m in 2024), organic growth of 13%, and a CHF 1.4m loss (CHF 4.3m in 2024).
The FDA validated Curatis’s corticorelin development plan in September 2025, enabling a regulatory submission supporting a pivotal PTBE study.
Curatis raised CHF 1.2m in November 2025; cash at December 31, 2025 was CHF 1.9m.
Under its March 2026 agreement with Neupharma Co., Ltd., Tokyo, Curatis will receive payments totaling up to CHF 83.5m and Japan royalties up to 20%.
Neupharma will finance and conduct the pivotal trial for children and adolescents; the clinical study is expected to start in 2027 after PMDA discussions planned for summer 2026.

Corticorelin is an investigational drug, not approved for therapeutic use in the United States or outside the United States. Curatis expects revenue growth of over 25% in 2026, while Curatis Group’s objective is to achieve a break even result in 2026.

Investor FAQs

Curatis Holding AG reported 2025 business revenues of CHF 10.8m, up 57%, and said it had achieved development and licensing milestones for corticorelin. The company also reported that its net loss narrowed to CHF 1.4m and that it had concluded a licensing agreement for corticorelin in Japan.

Source announcement

Company: Curatis Holding AG
Title: Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Published: Tuesday, 24 March 2026, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…